Q1fy17

Aurobindo Pharma shares gained nearly 3 percent intraday Wednesday after it received approvals from the US health regulator for three drugs, including Zoledronic filed from unit IV that inspected during the month.

Morgan Stanley cuts Idea target on lower forecast, guidance

Morgan Stanley has slashed target price of Idea Cellular to Rs 70 from Rs 89 earlier as it believes the share price will fall relative to the country index over the next 60 days.

Credit Suisse retains underperform on SAIL, valuations expensive

Credit Suisse has maintained underperform call on Steel Authority of India (SAIL) as the stock remained expensive even at FY18 EBITDA (earnings before interest, tax, depreciation and amortisation) and any deleveraging looks unlikely till FY19.

NBCC Q1 earnings may be strong, profit seen up 50% to Rs 66 cr

State-run construction company NBCC is likely to report a 50 percent growth in profit at Rs 66 crore and 24.5 percent growth in revenue at Rs 1,431 crore on yearly basis, according to average of estimates of analysts polled by CNBC-TV18.

Reliance Comm Q1 profit seen down 21%, EBITDA may grow 10%

Reliance Communications' first quarter profit is seen falling 20.9 percent sequentially to Rs 140 crore and revenue declining 1.5 percent to Rs 5,535 crore, according to average of estimates of analysts polled by CNBC-TV18.

Tata Steel Q1 loss widens 10-fold to Rs 3,183 cr, EBITDA up 21%

Tata Steel started off the financial year 2016-17 on a weak note with the consolidated quarterly loss widening 10-fold to Rs 3,183 crore compared with Rs 317 crore in same period last fiscal.

Tata Steel Q1 profit seen at Rs 292 cr, revenue may fall 4%

Tata Steel's first quarter profit is seen falling 61.7 percent to Rs 292 crore and revenue declining 3.9 percent to Rs 29,110 crore compared to year-ago period, according to average of estimates of analysts polled by CNBC-TV18.

GAIL can surprise on petchem, Q1 profit & revenue seen up 4%

GAIL is expected to continue its earnings revival in the quarter ended June 2016 with the profit & revenue rising 4 percent each to Rs 802 crore and Rs 12,152 crore on sequential basis, respectively.

Mahanagar Gas Q1 profit up 19% on strong operational performance

Operating profit (EBITDA - earnings before interest, tax, depreciation and amortisation) surged 20.4 percent year-on-year to Rs 152.3 crore and margin expanded 610 basis points to 28.5 percent in the quarter ended June 2016.

BPCL Q1 profit rises 11% to Rs 2620 cr, GRM at $6.09/bbl

Operating profit (EBITDA - earnings before interest, tax, depreciation and amortisation) grew by 3 percent year-on-year to Rs 3,919 crore and margin expanded by 37 basis points to 6.87 percent in June quarter.

Crompton gains 4%, analysts expect earnings to surprise in FY18

While maintaining outperform rating on the stock, Macquarie raised FY18 earnings per share forecast and target price by 6 percent (to Rs 92 from Rs 87) on the back of higher margin forecast.

BPCL Q1 profit seen down 12%, GRM likely to be $5/bbl

Earnings are likely to be moderate from a very strong performance in Q4FY16. Inventory gains will be closely watched for the quarter after it reported inventory loss of nearly Rs 1,000 crore in Q4FY16.

Crompton turns black, Q1 profit at Rs 40 cr; revenue rises 39%

Revenue increased 38.6 percent to Rs 1,423.76 crore during the quarter compared with Rs 1,027.52 crore in same period last year.

Crompton Q1 net seen at Rs 51 cr, industrial biz may aid revenue

Analysts expect strong revenue growth during the quarter as they see strong growth in the industrial segment.

IOC Q1 profit seen up over 3-fold, GRM may be at $4.6/bbl

Revenue is seen rising 20.6 percent to Rs 97,032 crore during the quarter compared with Rs 80,449.6 crore in previous quarter.

Tata Motors Q1 profit falls 57%, JLR revenue beats expectations

Tata Motors shares gained 2 percent on account of better-than-expected consolidated revenue growth & standalone operational performance, and improvement in JLR business.

Rakesh Jhunjhunwala's key questions to Aurobindo MD after Q1 nos

In earnings' conference call, Jhunjhunwala who currently holds 1.12 percent stake in the company threw a volley of questions to the management. The big bull raised questions on Aurobindo Pharma's finance cost, capex, rationale behind investment in vaccines, product launch, potential revenue growth and its fund raising plans.

Tata Power Q1 profit tanks 76% on one-time loss, revenue down 5%

Revenue also slipped 4.8 percent to Rs 6,838.3 crore during the quarter compared with Rs 7,183.7 crore in corresponding period of last fiscal.

Aurobindo Q1 profit seen up 30%, US biz may support revenue

Aurobindo Pharma's profit in April-June quarter may jump 29.6 percent year-on-year to Rs 560.3 crore and revenue is seen rising 15 percent to Rs 3,810.7 crore, according to average of estimates of analysts polled by CNBC-TV18.

Tata Power Q1 profit seen up 36%, Mundra volumes may be flat

Higher profitability at Maithon, higher EBIT spread for Coal and lower losses at Mundra may drive bottomline.

HPCL shines in Q1, profit jumps 30%; declares 2:1 bonus issue

Gross refining margin (GRM), the difference between total value of petroleum products and price of crude, stood at USD 6.83 a barrel during the quarter against USD 8.56 a barrel, which was far ahead of expectations of USD 4.9 per barrel.

NTPC Q1 profit rises 4%, operational performance beats estimates

NTPC said coal plant load factor improved to 81.35 percent during the quarter from 77.58 percent in same period last year. Average tariff in Q1 was at Rs 3.12 per unit against Rs 3.18 per unit in FY16.

Wockhardt Q1 profit sinks 83% on weak EBITDA; US, EM biz dip 16%

"US business, which contributed 18 percent of global revenue, degrew 16 percent," Wockhardt said. Emerging market business registered a 16 percent degrowth; and Irish 18 percent fall in rupee terms during the quarter.

Cipla Q1 profit down 44%, US biz drags revenue; MD to step down

Cipla said its MD & Global CEO Subhanu Saxena has stepped down effective August 31 and MK Hamied shall continue to hold position of non-executive vice chairman.

Sun Pharma Q1 profit soars 266% to Rs 2034cr, EBITDA surges 65%

The boost in bottomline was also on account of low base in year-ago period. The company had reported an exceptional loss of Rs 685.2 crore in Q1FY16 on account of integration and optimisation measures post Ranbaxy acquisition.